Zhengfang Yi

Synthesis and biological evaluation of cyanoenone- and enone-fused 4-androstene-3,17-dione derivatives against triple-negative breast cancer

Jing-Zan Zhang, Yunxuan Li, Jin-Hui Huang, Min Wu et autres

cn (code pays fourni par la source)

Figure S7 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma

Yajing Xing, Weikai Guo, Min Wu, Jiuqing Xie et autres

Figure S7. H&E staining of liver, spleen, lung and kidney from subcutaneous tumor xenografts mice treated with FX1 and WK692. Scale bars, 50 μm.

Figure S3 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma

Yajing Xing, Weikai Guo, Min Wu, Jiuqing Xie et autres

Figure S3. Quantitative ChIP assay was used to detect the enrichment of CDKN1A, CXCR4 and negative control region by NCOR in SUDHL4 cells exposed to 5 μM WK692 for 24 h. (*, P < 0.05 versus control)

Figure S2 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma

Yajing Xing, Weikai Guo, Min Wu, Jiuqing Xie et autres

Figure S2. WK692 specifically inhibits BCL6 but not other BTB-ZF Proteins. Reporter assays were performed to test the activity of WK692 with BCL6, Kaiso and PLZF. (***, P < 0.001 versus control).

Figure S4 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma

Yajing Xing, Weikai Guo, Min Wu, Jiuqing Xie et autres

Figure S4. Activation effect of BI3802, FX1 and WK692 on downstream gene of BCL6 at 10 µM. (*, P < 0.05; **, P < 0.01; ***, P < 0.001 versus control).

Figure S1 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma

Yajing Xing, Weikai Guo, Min Wu, Jiuqing Xie et autres

Figure S1. Chemical structures of FX1, BI3802 and WK692.

Figure S5 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma

Yajing Xing, Weikai Guo, Min Wu, Jiuqing Xie et autres

Figure S5. Viability of SUDHL4 and Farage cells transduced with shBCL6 or shScr was measured by CCK8 assay.

Figure S6 from A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma

Yajing Xing, Weikai Guo, Min Wu, Jiuqing Xie et autres

Figure S6. WK692 targets BCL6-BTB domain. (A) Computer docking assay predicted that WK692 bound to the BCL6-BTB domain. (B) The binding affinities were measured by SPR assay. (C) SUDHL4 shBCL6-1/shBCL6-2 cells were infected with lentivirus for re-expression of BCL6 (vector, WT, C53A) …

Targeting WFS1 overcomes KRASG12D dependency and adaptive resistance to KRAS inhibition in pancreatic cancer

Yu Chen, Jingwen Zhang, Ying Miao, Jiayu Wang et autres

KRAS G12D -driven pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge characterized by limited treatment options. While MRTX1133, a potent and selective KRAS G12D inhibitor, is currently under clinical evaluation, the emergence of acquired resistance restricts its long-term therapeutic efficacy. In this …

nz, cn (code pays fourni par la source)

A novel small-molecule inhibitor of IRF4 selectively suppresses multiple myeloma

Lin Zhang, Xin Ding, Min Wu, Jing-Zan Zhang et autres

Multiple myeloma (MM) is a highly aggressive hematologic malignancy that exploits transcriptional networks driven by IRF4 (interferon regulatory factor 4), an oncogenic protein that has been shown to directly mediate MM transcriptional networks. IRF4 overexpression promotes the proliferation of MM and the …

cn (code pays fourni par la source)

Supplementary Figures S1-S13 from Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer

Chen Huang, Wenbo Zhou, Aiwu Bian, Qiansen Zhang et autres

Fig. S1. Structure-based ligand discovery of STAT3 inhibitorsFig. S2. Surface plasmon resonance analysis of interactions between WB436B to STATfamily proteinsFig. S3. The biology evaluation of WB436B inactive analogue WB345Fig. S4. The mutation in STAT3 SH2 domain directly inhibited STAT3 transcriptionalactivitiesFig. S5. WB436B …

cn (code pays fourni par la source)

Supplementary Methods from Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer

Chen Huang, Wenbo Zhou, Aiwu Bian, Qiansen Zhang et autres

Supplementary Methods

cn (code pays fourni par la source)